AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21163686 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible-light therapy (VLT) device
Number of subjects: 20
Study 21163686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19089699 — intervention group
Group type: EXPERIMENTAL
Intervention: Health PSAs (public service announcements) focusing on nutrition, physical activity, and hand washing
Number of subjects: 0
Study 19089699 — intervention group
Group type: COMPARATOR
Intervention: Nonviewing counterparts (control group)
Number of subjects: 0
Study 17199681 — intervention group
Group type: EXPERIMENTAL
Intervention: Living bilayered skin construct (BSC)
Number of subjects: 177
Study 17199681 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (compression alone)
Number of subjects: 177
Study 17199681 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound Bed Score (WBS)
Number of subjects: 177
Study 17199681 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound Bed Score (WBS) quartile groups
Number of subjects: 177
Study 12599230 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin and ara-C (DA)
Number of subjects: 84
Study 12599230 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin and ara-C with thalidomide (DATh)
Number of subjects: 84
Study 12599230 — intervention group
Group type: COMPARATOR
Intervention: Liposomal daunorubicin and topotecan (DT)
Number of subjects: 84
Study 12599230 — intervention group
Group type: COMPARATOR
Intervention: Liposomal daunorubicin and topotecan with thalidomide (DTTh)
Number of subjects: 84
Study 10674229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia (Study I)
Number of subjects: 8
Study 10674229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia with maintenance of basal plasma AA and branched-chain KA concentrations (Study II)
Number of subjects: 8
Study 10674229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia with hyperaminoacidemia and basal plasma branched-chain KA concentrations (Study III)
Number of subjects: 8
Study 10674229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia plus basal plasma AA concentrations and elevated branched-chain KA levels (Study IV)
Number of subjects: 8
Study 9179456 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.05 mg/day x 21 days) and oral progestogens (10 mg/day medroxyprogesterone acetate [MPA] in the last 12 days, 10 mg/day dihydrogesterone in the last 12 days, and 50 mg/day cyproterone in the first 10 days)
Number of subjects: 38
Study 8456474 — intervention group
Group type: EXPERIMENTAL
Intervention: TDIS with OKT3 (group II)
Number of subjects: 129
Study 8456474 — intervention group
Group type: EXPERIMENTAL
Intervention: TDIS with LO-Tact-1 (group III)
Number of subjects: 129
Study 8456474 — intervention group
Group type: COMPARATOR
Intervention: TDIS only (group I)
Number of subjects: 129
Study 3531033 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (Aceten) 150 mg/day
Number of subjects: 39
Study 3531033 — intervention group
Group type: COMPARATOR
Intervention: M-dopa 750 mg/day
Number of subjects: 39
Study 30282510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexodyn solution on top of standard of care
Number of subjects: 50
Study 30282510 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 50
Study 28035345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavonoid fruit and vegetables (>15 mg/100 g)
Number of subjects: 0
Study 28035345 — intervention group
Group type: COMPARATOR
Intervention: Low-flavonoid fruit and vegetables (<5 mg/100 g)
Number of subjects: 0
Study 28035345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa drink (494 mg total flavanols)
Number of subjects: 0
Study 28035345 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol cocoa drink (23 mg total flavanols)
Number of subjects: 0
Study 24393456 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg)
Number of subjects: 0
Study 24393456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22892813 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanols (≈990 mg per day)
Number of subjects: 90
Study 22892813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate flavanols (≈520 mg per day)
Number of subjects: 90
Study 22892813 — intervention group
Group type: COMPARATOR
Intervention: Low flavanols (≈45 mg per day)
Number of subjects: 90
Study 20635829 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic medication voucher program providing a 30-day supply of 8 specific medications in addition to academic detailing.
Number of subjects: 108
Study 20635829 — intervention group
Group type: COMPARATOR
Intervention: Academic detailing alone (control group).
Number of subjects: 108
Study 20635829 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic medication voucher program.
Number of subjects: 108
Study 19273915 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with epinephrine 1:100,000
Number of subjects: 30
Study 19273915 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with epinephrine 1:100,000
Number of subjects: 30
Study 15681592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored smoking cessation intervention using AHCPR guideline with brief nurse-assisted counseling and follow-up telephone support.
Number of subjects: 401
Study 15681592 — intervention group
Group type: COMPARATOR
Intervention: Control group (201 patients) without the tailored intervention.
Number of subjects: 401
Study 15681592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored smoking cessation intervention for younger smokers (aged 49 or less).
Number of subjects: 401
Study 15681592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored smoking cessation intervention for older smokers (aged 50 or more).
Number of subjects: 401
Study 12629093 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg DHEA (n = 19)
Number of subjects: 39
Study 12629093 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 39
Study 12629093 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg DHEA
Number of subjects: 39
Study 10475655 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 250 mg at induction of anaesthesia, with a further three doses at 6-hourly intervals postoperatively
Number of subjects: 20
Study 10475655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically packaged)
Number of subjects: 20
Study 8738766 — intervention group
Group type: EXPERIMENTAL
Intervention: IMx assay for FK506 in whole blood samples
Number of subjects: 40
Study 8738766 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded samples
Number of subjects: 40
Study 1751266 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and midazolam combination
Number of subjects: 200
Study 1751266 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 200
Study 1751266 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 200
Study 1751266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propofol and midazolam
Number of subjects: 200
Study 7103030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with halothane anaesthesia
Number of subjects: 0
Study 7103030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with enflurane anaesthesia
Number of subjects: 0
Study 7103030 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl with various anaesthetic agents
Number of subjects: 0
Study 29528181 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan-cyclophosphamide-melphalan (Bu-Cy-Mel)
Number of subjects: 27
Study 29528181 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan-fludarabine (Bu-Flu)
Number of subjects: 27
Study 29528181 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (Bu-Cy-Mel and Bu-Flu)
Number of subjects: 27
Study 27630318 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (CCB) alone (1,000 mg/m2 bid p.o.)
Number of subjects: 24
Study 27630318 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (CCB) plus Cetuximab (CTX) (loading dose 400 mg/m2 followed by 250 mg/m2 weekly i.v. maintenance dose)
Number of subjects: 24
Study 25158772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy with clopidogrel and aspirin
Number of subjects: 3020
Study 25158772 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3020
Study 25158772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal major hemorrhage
Number of subjects: 3020
Study 21839429 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 40 mg triamcinolone, 2 ml bupivicaine, and 6 ml sterile water for injection
Number of subjects: 110
Study 21839429 — intervention group
Group type: COMPARATOR
Intervention: Group A: 40 mg triamcinolone and 2 ml bupivicaine
Number of subjects: 110
Study 20421430 — intervention group
Group type: COMPARATOR
Intervention: 1.5% dextrose solution
Number of subjects: 13
Study 20421430 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% amino acid solution
Number of subjects: 13
Study 18287602 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 654
Study 18287602 — intervention group
Group type: COMPARATOR
Intervention: Usual nonsurgical care
Number of subjects: 654
Study 18287602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined as-treated analysis (surgery)
Number of subjects: 654
Study 15807814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pointed microneedle injections
Number of subjects: 11
Study 15807814 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric microneedle injections
Number of subjects: 11
Study 15807814 — intervention group
Group type: COMPARATOR
Intervention: Topical application (TA)
Number of subjects: 11
Study 12747504 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision time as a measure of conflict strength
Number of subjects: 0
Study 10850522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gatifloxacin 400 mg
Number of subjects: 24
Study 10850522 — intervention group
Group type: COMPARATOR
Intervention: Oral gatifloxacin 400 mg
Number of subjects: 24
Study 8790227 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone at a dose of 0.025 mg/kg body weight/day administered by daily subcutaneous injection over a 6-month study period
Number of subjects: 33
Study 8790227 — intervention group
Group type: COMPARATOR
Intervention: Estrogen (not specified dosage or duration)
Number of subjects: 33
Study 8790227 — intervention group
Group type: COMPARATOR
Intervention: Younger women (20 to 40 years)
Number of subjects: 33
Study 1637766 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 100
Study 1637766 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic (2% lignocaine and 0.03 iu/ml octopressin)
Number of subjects: 100
Study 1637766 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS plus local anaesthetic
Number of subjects: 100
Study 6398314 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin 50 mg, i.v., 3 times a week for 3 consecutive weeks
Number of subjects: 41
Study 6398314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 6398314 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 41
Study 30963239 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (4 × 4‐min intervals)
Number of subjects: 12
Study 30963239 — intervention group
Group type: EXPERIMENTAL
Intervention: ST (five body‐weight exercises)
Number of subjects: 12
Study 30963239 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (continuous cycling)
Number of subjects: 12
Study 30963239 — intervention group
Group type: EXPERIMENTAL
Intervention: Squats (part of ST)
Number of subjects: 12
Study 30963239 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-ups (part of ST)
Number of subjects: 12
Study 28270276 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 kV group (n=20)
Number of subjects: 40
Study 28270276 — intervention group
Group type: COMPARATOR
Intervention: 100 kV group (n=20)
Number of subjects: 40
Study 27798038 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise (CBE) intervention, 24-week program including aerobic, resistance, balance, and flexibility exercise at the YMCA, 3 times per week with supervision and educational sessions.
Number of subjects: 0
Study 24441150 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab + MTX
Number of subjects: 333
Study 24441150 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 333
Study 22079469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beclomethasone dipropionate (BDP) administered as 1-mg immediate-release formulation plus 1-mg delayed-release formulation orally four times daily.
Number of subjects: 138
Study 22079469 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as per the study design.
Number of subjects: 138
Study 22079469 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to the study drug during the first 4 weeks after hematopoietic cell transplantation.
Number of subjects: 138
Study 22079469 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the study drug schedule.
Number of subjects: 138
Study 19153943 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine
Number of subjects: 77
Study 19153943 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 77
Study 19153943 — intervention group
Group type: COMPARATOR
Intervention: drug-free
Number of subjects: 77
Study 19153943 — intervention group
Group type: EXPERIMENTAL
Intervention: free IGF-I
Number of subjects: 77
Study 17156883 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10mg, t.i.d. for 7 days
Number of subjects: 39
Study 17156883 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10mg, t.i.d. for 7 days (in patients with ascites)
Number of subjects: 39
Study 17156883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16335037 — intervention group
Group type: COMPARATOR
Intervention: TG0 (no coronal walls)
Number of subjects: 40
Study 16335037 — intervention group
Group type: EXPERIMENTAL
Intervention: TG1 (one coronal wall)
Number of subjects: 40
Study 16335037 — intervention group
Group type: EXPERIMENTAL
Intervention: TG2 (two coronal walls)
Number of subjects: 40
Study 16335037 — intervention group
Group type: EXPERIMENTAL
Intervention: TG3 (three coronal walls)
Number of subjects: 40
Study 10961470 — intervention group
Group type: COMPARATOR
Intervention: Urodynamic examination before and after delayed treatment starting 6 months after inclusion in the study (Control group)
Number of subjects: 87
Study 10961470 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic examination only after the final outcome evaluation at 12 months (Intervention group)
Number of subjects: 87
Study 9194908 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-flavored human milk
Number of subjects: 0
Study 9194908 — intervention group
Group type: COMPARATOR
Intervention: Unaltered human milk
Number of subjects: 0
Study 1553612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube
Number of subjects: 109
Study 1553612 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube
Number of subjects: 109
Study 3158563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fominoben (PB89) - 160 mg, 3 times a day for 2 weeks
Number of subjects: 60
Study 3158563 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan - 30 mg, 3 times a day for 2 weeks
Number of subjects: 60
Study 29398337 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g/d prunes (plus 300 ml/d water)
Number of subjects: 120
Study 29398337 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 g/d prunes (plus 300 ml/d water)
Number of subjects: 120
Study 29398337 — intervention group
Group type: COMPARATOR
Intervention: Control (300 ml/d water)
Number of subjects: 120
Study 29398337 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g/d prunes
Number of subjects: 120
Study 29398337 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 g/d prunes
Number of subjects: 120
Study 29398337 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 29398337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prune consumption
Number of subjects: 120
Study 29398337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prunes
Number of subjects: 120
Study 29504445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression therapy in addition to conventional postoperative rehabilitation
Number of subjects: 115
Study 29504445 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative rehabilitation without intermittent pneumatic compression therapy
Number of subjects: 115
Study 27450411 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin maintenance therapy (250/500 mg according to body weight) administered three times a week for 6 months
Number of subjects: 125
Study 27450411 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin maintenance therapy
Number of subjects: 125
Study 27450411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 23290692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 20648883 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured comprehensive oral health education (SC‐OHE)
Number of subjects: 4210
Study 20648883 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral health education (Control Group)
Number of subjects: 4210
Study 18386538 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg, tablet)
Number of subjects: 80
Study 18386538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16888468 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical education classes (first or second semester)
Number of subjects: 214
Study 16888468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (some or meeting Healthy People 2010 guidelines)
Number of subjects: 214
Study 16888468 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 214
Study 16888468 — intervention group
Group type: COMPARATOR
Intervention: Physical education class enrollment or physical activity levels
Number of subjects: 214
Study 12796154 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micro g)
Number of subjects: 67
Study 12796154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micro g)
Number of subjects: 67
Study 12796154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 10860897 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/didanosine/nevirapine
Number of subjects: 74
Study 10860897 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine/delavirdine
Number of subjects: 74
Study 8864639 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1-8 mg/day, once daily)
Number of subjects: 2000
Study 8864639 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 2000
Study 1332433 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional therapy
Number of subjects: 89
Study 1332433 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 89
Study 3006981 — intervention group
Group type: EXPERIMENTAL
Intervention: 40, 80, or 160 mg propranolol (non‐selective blockade)
Number of subjects: 6
Study 3006981 — intervention group
Group type: EXPERIMENTAL
Intervention: 25, 50, or 100 mg atenolol (beta 1‐selective blockade)
Number of subjects: 6
Study 3006981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31883330 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA-guided management
Number of subjects: 4146
Study 31883330 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus CTCA
Number of subjects: 4146
Study 29289579 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions (exercise on a Swiss ball, lumbosacral massage, warm shower)
Number of subjects: 80
Study 29289579 — intervention group
Group type: COMPARATOR
Intervention: Usual maternity unit care
Number of subjects: 80
Study 29289579 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 80
Study 26094600 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid Index (AFI)
Number of subjects: 1052
Study 26094600 — intervention group
Group type: COMPARATOR
Intervention: Single Deepest Vertical Pocket (SDP)
Number of subjects: 1052
Study 24438582 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions focusing on changing beliefs and cognitions related to sexual practices (Mankweng, Limpopo, South Africa)
Number of subjects: 0
Study 24438582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention promoting improved parent-offspring communication on sexuality (Kampala, Uganda)
Number of subjects: 0
Study 24438582 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention promoting healthy sexual practices (Western Cape, South Africa)
Number of subjects: 0
Study 24438582 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based peer education intervention (Dar es Salaam, Tanzania)
Number of subjects: 0
Study 24438582 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention arms (control group)
Number of subjects: 0
Study 22387995 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational and self-efficacy variables
Number of subjects: 849
Study 22387995 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous quit attempts
Number of subjects: 849
Study 22387995 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 849
Study 20143382 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaith spiritually based intervention (SBI)
Number of subjects: 22
Study 20143382 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 22
Study 20143382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SBI and CBT
Number of subjects: 22
Study 18391642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 200
Study 18391642 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 200